

**RECEIVED**  
**CENTRAL FAX CENTER**  
**DEC 05 2008**

Attorney Docket No. 9022-41

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Maurer et al.

Application Serial No.: 10/767,352

Filed: January 30, 2004

For: *Oral Compositions of Fenretinide Having Increased Bioavailability and Methods of Using the Same*

Confirmation No.: 4884

Group Art Unit: 1618

Examiner: Blessing M. Fubara

Date: December 5, 2008

## MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**AMENDMENT RESPONSIVE TO**  
**OFFICE ACTION DATED SEPTEMBER 5, 2008**

Sir/Madam:

This response is submitted in reply to the Office Action dated September 5, 2008. It is respectfully requested that this application be reconsidered in view of the following amendments and remarks presented herein.

It is not believed that any fee(s), including fees for additional claims, are required, beyond those that may otherwise be provided for in documents accompanying this submission. In the event, however, that any requests, petitions or extensions of time for the accompanying response are required to prevent abandonment of this application, Applicants submit that such an extension is also hereby petitioned for under 37 C.F.R. §1.136(a) and/or a request be granted pursuant to 37 C.F.R. §1.114. Any additional fees believed to be due in connection with this submission may be charged to our Deposit Account No. 50-0220, or any overpayment may be credited to the same.

**Amendments to the Specification** begin on page 2 of this document.

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2 of this document.

**Remarks** begin on page 6 of this document.